Coleman Mark 4

What Happened

• Mark Coleman, a director of Axsome Therapeutics (AXSM), exercised stock options on 2026-02-10 to acquire 5,193 shares by paying $8.02 per share (total cash paid ≈ $41,648). The Form 4 also reports a corresponding disposition of 5,193 derivative securities at $0, which reflects the conversion of the options into common stock. According to the filing, the shares were acquired in a cash exercise and are being held rather than sold.

Key Details

• Transaction date: 2026-02-10
• Exercise price / purchase price: $8.02 per share
• Shares acquired: 5,193; Cash paid ≈ $41,648
• Derivative disposition: 5,193 listed at $0 (represents conversion of options to shares)
• Shares owned after transaction: not specified in the provided filing
• Footnotes: F1 = cash exercise and hold of underlying shares; F2 = shares are held by an entity of which Coleman has voting/dispositive power (indirect beneficial ownership)
• Filing timeliness: Report appears filed the same day (2026-02-10); no late filing indicated in the provided data

Context

• This was an options exercise (transaction code M). The derivative-disposition line is standard when options are converted into shares—it's not a market sale. Because the shares are held by an entity Coleman controls, the filing treats him as an indirect beneficial owner. Exercises are routine for insiders with option grants and do not by themselves indicate a clear bullish or bearish signal.